Loading company…
Tisento Therapeutics develops medicines for conditions with high unmet medical needs.
Tisento Therapeutics develops medicines for conditions with high unmet medical needs. In July 2023, the Cambridge, Massachusetts company raised USD 81 million in Series A funding from Sanofi Ventures, Venrock and J. Wood Capital, alongside individual and other investors. The funding is intended to support Phase 2 development of soluble guanylate cyclase stimulator zagociguat.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in